JP2018506961A5 - - Google Patents

Download PDF

Info

Publication number
JP2018506961A5
JP2018506961A5 JP2017532709A JP2017532709A JP2018506961A5 JP 2018506961 A5 JP2018506961 A5 JP 2018506961A5 JP 2017532709 A JP2017532709 A JP 2017532709A JP 2017532709 A JP2017532709 A JP 2017532709A JP 2018506961 A5 JP2018506961 A5 JP 2018506961A5
Authority
JP
Japan
Prior art keywords
antibody
seq
domain
axl
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017532709A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018506961A (ja
JP6931609B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/080654 external-priority patent/WO2016097370A2/en
Publication of JP2018506961A publication Critical patent/JP2018506961A/ja
Publication of JP2018506961A5 publication Critical patent/JP2018506961A5/ja
Priority to JP2021033363A priority Critical patent/JP2021101707A/ja
Application granted granted Critical
Publication of JP6931609B2 publication Critical patent/JP6931609B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017532709A 2014-12-18 2015-12-18 抗Axlアンタゴニスト抗体 Expired - Fee Related JP6931609B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021033363A JP2021101707A (ja) 2014-12-18 2021-03-03 抗Axlアンタゴニスト抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1422605.4 2014-12-18
GB201422605 2014-12-18
PCT/EP2015/080654 WO2016097370A2 (en) 2014-12-18 2015-12-18 Anti-axl antagonistic antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021033363A Division JP2021101707A (ja) 2014-12-18 2021-03-03 抗Axlアンタゴニスト抗体

Publications (3)

Publication Number Publication Date
JP2018506961A JP2018506961A (ja) 2018-03-15
JP2018506961A5 true JP2018506961A5 (enExample) 2019-01-24
JP6931609B2 JP6931609B2 (ja) 2021-09-08

Family

ID=55080088

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017532709A Expired - Fee Related JP6931609B2 (ja) 2014-12-18 2015-12-18 抗Axlアンタゴニスト抗体
JP2021033363A Pending JP2021101707A (ja) 2014-12-18 2021-03-03 抗Axlアンタゴニスト抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021033363A Pending JP2021101707A (ja) 2014-12-18 2021-03-03 抗Axlアンタゴニスト抗体

Country Status (9)

Country Link
US (3) US10208121B2 (enExample)
EP (1) EP3233119A2 (enExample)
JP (2) JP6931609B2 (enExample)
KR (1) KR102453227B1 (enExample)
CN (2) CN116410318A (enExample)
AU (1) AU2015366213B2 (enExample)
CA (1) CA2969879A1 (enExample)
MX (1) MX390849B (enExample)
WO (1) WO2016097370A2 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201410825D0 (en) * 2014-06-18 2014-07-30 Bergenbio As Anti-axl antibodies
GB201410826D0 (en) * 2014-06-18 2014-07-30 Bergenbio As Anti-axl antibodies
AU2015366213B2 (en) * 2014-12-18 2021-10-07 Bergenbio Asa Anti-Axl antagonistic antibodies
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
GB201509338D0 (en) 2015-05-29 2015-07-15 Bergenbio As Combination therapy
GB201610902D0 (en) * 2016-06-22 2016-08-03 Bergen Teknologioverforing As And Bergenbio As Anti-Axl Antagonistic Antibodies
WO2019017401A1 (ja) * 2017-07-18 2019-01-24 協和発酵キリン株式会社 抗ヒトccr1モノクローナル抗体
MA52657A (fr) * 2018-04-10 2021-02-17 Genmab As Anticorps spécifiques d'axl pour le traitement du cancer
JP2021523379A (ja) * 2018-05-14 2021-09-02 ベルゲンビオ アーエスアー 血清バイオマーカー
CN110540592B (zh) 2018-05-29 2022-08-09 杭州尚健生物技术有限公司 结合axl蛋白的抗体及其应用
CN109206490A (zh) * 2018-09-29 2019-01-15 未名生物医药有限公司 蛋白序列11b09及其用途
CN109206489A (zh) * 2018-09-29 2019-01-15 未名生物医药有限公司 蛋白序列12g12及其用途
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
WO2020205576A1 (en) * 2019-03-29 2020-10-08 Celldex Therapeutics, Inc. Anti-axl antibodies and methods of use thereof
GB201912059D0 (en) 2019-08-22 2019-10-09 Bergenbio As Combaination therapy of a patient subgroup
WO2021154156A1 (en) * 2020-01-31 2021-08-05 Agency For Science, Technology And Research Anti-axl antibody and uses thereof
CN115210263A (zh) 2020-02-28 2022-10-18 西福根有限公司 抗axl抗体和组合物
GB202004189D0 (en) 2020-03-23 2020-05-06 Bergenbio As Combination therapy
CN115916344A (zh) 2020-04-08 2023-04-04 卑尔根生物股份公司 用于抗病毒疗法的axl抑制剂
GB202006072D0 (en) 2020-04-24 2020-06-10 Bergenbio Asa Method of selecting patients for treatment with cmbination therapy
CN116635064A (zh) 2020-12-18 2023-08-22 世纪治疗股份有限公司 具有适应性受体特异性的嵌合抗原受体系统
KR102549520B1 (ko) 2021-01-29 2023-07-03 일리미스테라퓨틱스 주식회사 비염증성 식세포작용 유도 활성을 갖는 융합분자
GB202104037D0 (en) 2021-03-23 2021-05-05 Bergenbio Asa Combination therapy
WO2022261846A1 (zh) * 2021-06-16 2022-12-22 上海鑫湾生物科技有限公司 靶向axl蛋白的抗体及其抗原结合片段、其制备方法和应用
TW202440636A (zh) * 2023-03-21 2024-10-16 美商傳記55有限公司 Cd19/cd38多特異性抗體

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1382969A1 (en) 2002-07-17 2004-01-21 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Diagnosis and prevention of cancer cell invasion
CN101939336B (zh) * 2007-11-12 2014-05-14 U3制药有限公司 Axl抗体
TW200936160A (en) * 2007-11-15 2009-09-01 Chugai Pharmaceutical Co Ltd Monoclonal antibodies that bind to anexelekto and uses thereof
MX2011011825A (es) 2009-05-11 2011-12-06 U3 Pharma Gmbh Anticuerpos humanizados para axl.
AR077595A1 (es) 2009-07-27 2011-09-07 Genentech Inc Tratamientos de combinacion
WO2011159980A1 (en) * 2010-06-18 2011-12-22 Genentech, Inc. Anti-axl antibodies and methods of use
US20130237456A1 (en) 2011-05-06 2013-09-12 Jia Fan Marker consisting of plasma microrna and a new method for diagnosis of hepatocellular carcinoma
WO2012175692A1 (en) * 2011-06-22 2012-12-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-axl antibodies and uses thereof
JP6033293B2 (ja) 2011-06-22 2016-11-30 インサーム(インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル)Inserm(Institut National Dela Sante Et De La Recherche Medicale) 抗Axl抗体及びその使用
EP2589609A1 (en) * 2011-11-03 2013-05-08 Pierre Fabre Medicament Antigen binding protein and its use as addressing product for the treatment of cancer
US9879061B2 (en) * 2011-12-15 2018-01-30 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of AXL/GAS6 signaling in the treatment of liver fibrosis
IN2015DN00188A (enExample) 2012-06-29 2015-06-12 Mitsubishi Gas Chemical Co
US9624308B2 (en) 2012-11-05 2017-04-18 Pierre Fabre Medicament Antigen binding proteins
GB201410826D0 (en) * 2014-06-18 2014-07-30 Bergenbio As Anti-axl antibodies
GB201410825D0 (en) * 2014-06-18 2014-07-30 Bergenbio As Anti-axl antibodies
US9986723B2 (en) * 2014-10-22 2018-06-05 The Board Of Regents Of The University Of Texas System Screen and use of therapeutics for pancreatic ductal adenocarcinoma
AU2015366213B2 (en) * 2014-12-18 2021-10-07 Bergenbio Asa Anti-Axl antagonistic antibodies
GB201610902D0 (en) * 2016-06-22 2016-08-03 Bergen Teknologioverforing As And Bergenbio As Anti-Axl Antagonistic Antibodies

Similar Documents

Publication Publication Date Title
JP2018506961A5 (enExample)
TWI854953B (zh) 抗cd3抗體及含有該抗體的分子、及其製造方法
JP2017535257A5 (enExample)
JP2022177090A5 (enExample)
JP2017526339A5 (enExample)
JP2019201643A5 (enExample)
JP2017519501A5 (enExample)
JP2017514461A5 (enExample)
JP2020510422A5 (enExample)
JP2021518103A5 (enExample)
JP2015163068A5 (enExample)
JP2019528677A5 (enExample)
JP2013519364A5 (enExample)
JP2020514277A5 (enExample)
JP2020515247A5 (enExample)
JP2014509835A5 (enExample)
US20250034273A1 (en) Composition of multispecific antibodies targeting cadherin-17-expressing tumors and method of making and using thereof
JP2017521054A5 (enExample)
JP7679399B2 (ja) 抗flt3抗体及び組成物
JP2010509931A5 (enExample)
JP2020534012A5 (enExample)
JP2020522280A5 (enExample)
JP2022507485A (ja) Cd38抗体とicam1抗体およびそれらの使用
JP2020513759A5 (enExample)
JP2018528759A5 (enExample)